PMID- 12811631
OWN - NLM
STAT- MEDLINE
DCOM- 20040408
LR  - 20180813
IS  - 0914-8779 (Print)
IS  - 0914-8779 (Linking)
VI  - 21
IP  - 4
DP  - 2003
TI  - Low serum levels of intact osteocalcin in patients with congestive heart failure.
PG  - 247-52
AB  - Impaired bone metabolism is a frequent complication following heart 
      transplantation. Little is known, however, about possible alterations in bone 
      turnover of pretransplant patients with congestive heart failure (CHF). We 
      therefore studied biomarkers of bone turnover in 21 male patients with CHF (New 
      York Heart Association [NYHA] classification > II) compared with 21 controls 
      (NYHA classification < II). Biomarkers of bone formation (intact osteocalcin and 
      carboxy-terminal propeptide of type I collagen), markers of bone resorption 
      (N-telopeptide and C-telopeptide of type I collagen), undercarboxylated 
      osteocalcin (an indicator of fracture risk), and concentrations of calcium, 
      parathyroid hormone, and vitamin D metabolites (25-hydroxyvitamin D and 
      calcitriol) were measured in fasting blood samples. Serum levels of intact 
      osteocalcin were 44.5% lower (P < 0.01), and the ratio of 
      undercarboxylated-to-intact osteocalcin was 113% higher (P < 0.01) in the 
      patients in comparison with the controls. Moreover, patients had 34% lower 
      25-hydroxyvitamin D levels (P < 0.01) and 22% lower calcitriol levels (P < 0.05) 
      than the controls. The bone resorption markers, N-telopeptide and C-telopeptide; 
      the bone formation marker, carboxy-terminal propeptide of type I collagen; 
      parathyroid hormone levels; and albumin-adjusted serum calcium concentrations did 
      not differ between patients and controls (all P values > 0.05). In summary, there 
      were no biochemical signs of enhanced bone collagen resorption in pretransplant 
      CHF patients. However, the low serum levels of intact osteocalcin and the high 
      ratio of undercarboxylated-to-intact osteocalcin deserve further consideration.
FAU - Schleithoff, Stefanie Schulze
AU  - Schleithoff SS
AD  - Department of Nutrition Science, University of Bonn, Endenicher Allee 11-13, 
      53115 Bonn, Germany.
FAU - Zittermann, Armin
AU  - Zittermann A
FAU - Stuttgen, Benjamin
AU  - Stuttgen B
FAU - Tenderich, Gero
AU  - Tenderich G
FAU - Berthold, Heiner K
AU  - Berthold HK
FAU - Korfer, Reiner
AU  - Korfer R
FAU - Stehle, Peter
AU  - Stehle P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - J Bone Miner Metab
JT  - Journal of bone and mineral metabolism
JID - 9436705
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Collagen Type I)
RN  - 0 (Parathyroid Hormone)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (Procollagen)
RN  - 0 (collagen type I trimeric cross-linked peptide)
RN  - 0 (procollagen type I carboxy terminal peptide)
RN  - 104982-03-8 (Osteocalcin)
RN  - 1406-16-2 (Vitamin D)
RN  - 9007-34-5 (Collagen)
RN  - A288AR3C9H (25-hydroxyvitamin D)
RN  - FXC9231JVH (Calcitriol)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aged
MH  - Anticoagulants/therapeutic use
MH  - Biomarkers/analysis
MH  - Bone Resorption/metabolism
MH  - Calcitriol/blood
MH  - Calcium/blood
MH  - Case-Control Studies
MH  - Collagen/blood
MH  - Collagen Type I
MH  - Heart Failure/*blood/drug therapy/metabolism
MH  - Humans
MH  - Male
MH  - Osteocalcin/*blood/drug effects
MH  - Parathyroid Hormone/blood
MH  - Peptide Fragments/blood
MH  - Peptides/blood
MH  - Procollagen/blood
MH  - Vitamin D/*analogs & derivatives/blood
EDAT- 2003/06/18 05:00
MHDA- 2004/04/09 05:00
CRDT- 2003/06/18 05:00
PHST- 2003/06/18 05:00 [pubmed]
PHST- 2004/04/09 05:00 [medline]
PHST- 2003/06/18 05:00 [entrez]
AID - 10.1007/s00774-003-0417-7 [doi]
PST - ppublish
SO  - J Bone Miner Metab. 2003;21(4):247-52. doi: 10.1007/s00774-003-0417-7.